Tilray Brands, Inc. specializes in the research, cultivation, and distribution of medical cannabis products across multiple regions. Key strengths include a solid current ratio of 1.88, indicating good liquidity, and a gross margin of 30.1%, suggesting effective cost management. However, concerns arise from negative EBITDA and net margins, reflecting ongoing profitability challenges. The low debt-to-equity ratio of 0.23 is a positive sign of manageable leverage, but the overall financial health score of 63/100 indicates room for improvement.
Loading financial metrics...
Company posted a loss of $-164.2M over the last year, representing 17.1% of revenue.
Operating cash flow has been negative for 3 consecutive quarters, burning $84.3M over the last year.
Strong revenue growth of 15.9% YoY indicates solid business momentum.
Operating margin expanded by 244.8pp, demonstrating strong operational leverage.
Both gross margin (+0.4pp) and operating margin (+244.8pp) are expanding simultaneously, indicating the company is scaling profitably.
Valuation, risk assessment, competitive positioning, and key insights — all in one report.
Other Drug Manufacturers - Specialty & Generic companies of a similar size
Based on 2027-Q1 (August 31, 2026)